RU2005119309A - Способ перитонеального диализа - Google Patents
Способ перитонеального диализа Download PDFInfo
- Publication number
- RU2005119309A RU2005119309A RU2005119309/15A RU2005119309A RU2005119309A RU 2005119309 A RU2005119309 A RU 2005119309A RU 2005119309/15 A RU2005119309/15 A RU 2005119309/15A RU 2005119309 A RU2005119309 A RU 2005119309A RU 2005119309 A RU2005119309 A RU 2005119309A
- Authority
- RU
- Russia
- Prior art keywords
- salt
- adenosine triphosphate
- peritoneal
- glucose
- dialysate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 11
- 238000000502 dialysis Methods 0.000 title claims 8
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims 12
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 11
- 239000008103 glucose Substances 0.000 claims 11
- 230000005779 cell damage Effects 0.000 claims 6
- 230000006378 damage Effects 0.000 claims 6
- 239000003792 electrolyte Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 210000003245 peritoneal mesothelial cell Anatomy 0.000 claims 3
- 210000000683 abdominal cavity Anatomy 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 210000004303 peritoneum Anatomy 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000037887 cell injury Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
- Medicinal Preparation (AREA)
Claims (20)
1. Перитонеальный диализат, содержащий аденозинтрифосфат или его соль.
2. Перитонеальный диализат по п.1, дополнительно содержащий глюкозу и электролит.
3. Профилактическое или терапевтическое средство для лечения повреждений брюшины, включающее аденозинтрифосфат или его соль в качестве активного ингредиента.
4. Средство для лечения клеточных повреждений, вызванных сахаром, включающее аденозинтрифосфат или его соль в качестве активного ингредиента.
5. Средство по п.4, где клеточное повреждение, вызванное сахаром, представляет собой повреждение мезотелиальных клеток брюшины, вызванное глюкозой.
6. Применение аденозинтрифосфата или его соли для изготовления перитонеального диализата.
7. Применение по п.6, где перитонеальный диализат, дополнительно, содержит глюкозу и электролит.
8. Применение аденозинтрифосфата или его соли для изготовления профилактического или терапевтического средства для лечения повреждения брюшины.
9. Применение аденозинтрифосфата или его соли для изготовления средства для лечения клеточных повреждений, вызванных сахаром.
10. Применение по п.9, где клеточное повреждение, вызванное сахаром, представляет собой повреждение мезотелиальных клеток брюшины, вызванное глюкозой.
11. Способ перитонеального диализа, отличающийся тем, что предусматривает применение диализата, содержащего аденозинтрифосфат или его соль в эффективном количестве.
12. Способ перитонеального диализа по п.11, содержащий внутрибрюшинное введение диализата, содержащего эффективное количество аденозинтрифосфата или его соли, через катетер, имплантированный в брюшную полость пациента, страдающего почечным заболеванием.
13. Способ перитонеального диализа по п.11 или 12, где содержание аденозинтрифосфата или его соли в диализате составляет от 10 до 5000 мкМ.
14. Способ перитонеального диализа по п.11 или 12, где диализат, дополнительно, включает глюкозу и электролит.
15. Способ перитонеального диализа по п.14, где содержание глюкозы составляет от 1000 до 4000 мг/дкл.
16. Способ перитонеального диализа по п.11, содержащий внутрибрюшинное введение через катетер, имплантированный в брюшную полость пациенту, страдающему почечным заболеванием, диализата, содержащего эффективное количество аденозинтрифосфата или его соли и физиологический уровень глюкозы перед введением диализата, содержащего глюкозу в высокой концентрации.
17. Способ перитонеального диализа по п.16, где физиологическое содержание глюкозы составляет от 0,08 до 0,16% (мас./об.), а высокое содержание глюкозы составляет от 1000 до 4000 мг/дкл.
18. Способ лечения повреждения брюшины, отличающийся тем, что вводят аденозинтрифосфат или его соль в эффективном количестве.
19. Способ лечения клеточного повреждения, вызванного сахаром, отличающийся тем, что вводят аденозинтрифосфат или его соль в эффективном количестве.
20. Способ по п.19, где клеточное повреждение, вызванное сахаром, представляет собой повреждение мезотелиальных клеток брюшины, вызванное глюкозой.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42798002P | 2002-11-21 | 2002-11-21 | |
| US60/427,980 | 2002-11-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005119309A true RU2005119309A (ru) | 2006-01-20 |
| RU2353400C2 RU2353400C2 (ru) | 2009-04-27 |
Family
ID=32326623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005119309/15A RU2353400C2 (ru) | 2002-11-21 | 2003-11-20 | Способ перитонеального диализа |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8222229B2 (ru) |
| EP (1) | EP1563858A4 (ru) |
| JP (1) | JP4463687B2 (ru) |
| KR (1) | KR101057082B1 (ru) |
| CN (1) | CN1713926B (ru) |
| AU (2) | AU2003284594B2 (ru) |
| CA (1) | CA2506704C (ru) |
| NZ (1) | NZ539796A (ru) |
| RU (1) | RU2353400C2 (ru) |
| WO (1) | WO2004045679A1 (ru) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235589B2 (en) * | 2004-09-21 | 2007-06-26 | Bio Numerik Pharmaceuticals, Inc. | Method of treating patients undergoing kidney dialysis |
| ES2400001T3 (es) | 2007-03-02 | 2013-04-04 | Zytoprotec Gmbh | Fluido de diálisis peritoneal basado en carbohidratos que comprende residuo de glutamina |
| TW200936619A (en) | 2007-11-15 | 2009-09-01 | Univation Tech Llc | Polymerization catalysts, methods of making, methods of using, and polyolefin products made therefrom |
| US8992517B2 (en) | 2008-04-29 | 2015-03-31 | Virginia Tech Intellectual Properties Inc. | Irreversible electroporation to treat aberrant cell masses |
| US10238447B2 (en) | 2008-04-29 | 2019-03-26 | Virginia Tech Intellectual Properties, Inc. | System and method for ablating a tissue site by electroporation with real-time monitoring of treatment progress |
| US11272979B2 (en) | 2008-04-29 | 2022-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US10245098B2 (en) | 2008-04-29 | 2019-04-02 | Virginia Tech Intellectual Properties, Inc. | Acute blood-brain barrier disruption using electrical energy based therapy |
| US9867652B2 (en) | 2008-04-29 | 2018-01-16 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds |
| US9198733B2 (en) | 2008-04-29 | 2015-12-01 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for electroporation-based therapies |
| WO2009134876A1 (en) | 2008-04-29 | 2009-11-05 | Virginia Tech Intellectual Properties, Inc. | Irreversible electroporation to create tissue scaffolds |
| US11254926B2 (en) | 2008-04-29 | 2022-02-22 | Virginia Tech Intellectual Properties, Inc. | Devices and methods for high frequency electroporation |
| US10702326B2 (en) | 2011-07-15 | 2020-07-07 | Virginia Tech Intellectual Properties, Inc. | Device and method for electroporation based treatment of stenosis of a tubular body part |
| US10448989B2 (en) | 2009-04-09 | 2019-10-22 | Virginia Tech Intellectual Properties, Inc. | High-frequency electroporation for cancer therapy |
| US10272178B2 (en) | 2008-04-29 | 2019-04-30 | Virginia Tech Intellectual Properties Inc. | Methods for blood-brain barrier disruption using electrical energy |
| US9283051B2 (en) | 2008-04-29 | 2016-03-15 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating a treatment volume for administering electrical-energy based therapies |
| US10117707B2 (en) | 2008-04-29 | 2018-11-06 | Virginia Tech Intellectual Properties, Inc. | System and method for estimating tissue heating of a target ablation zone for electrical-energy based therapies |
| US8632534B2 (en) | 2009-04-03 | 2014-01-21 | Angiodynamics, Inc. | Irreversible electroporation (IRE) for congestive obstructive pulmonary disease (COPD) |
| US11638603B2 (en) | 2009-04-09 | 2023-05-02 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
| US11382681B2 (en) | 2009-04-09 | 2022-07-12 | Virginia Tech Intellectual Properties, Inc. | Device and methods for delivery of high frequency electrical pulses for non-thermal ablation |
| US8903488B2 (en) | 2009-05-28 | 2014-12-02 | Angiodynamics, Inc. | System and method for synchronizing energy delivery to the cardiac rhythm |
| US9895189B2 (en) | 2009-06-19 | 2018-02-20 | Angiodynamics, Inc. | Methods of sterilization and treating infection using irreversible electroporation |
| ES2365429B1 (es) * | 2010-03-05 | 2012-09-06 | Universidad De Castilla De La Mancha | Solucion para dialisis peritoneal |
| US8425455B2 (en) | 2010-03-30 | 2013-04-23 | Angiodynamics, Inc. | Bronchial catheter and method of use |
| WO2012025602A1 (en) | 2010-08-26 | 2012-03-01 | Vib Vzw | Insect binding antibodies |
| WO2012051433A2 (en) | 2010-10-13 | 2012-04-19 | Angiodynamics, Inc. | System and method for electrically ablating tissue of a patient |
| JP5941476B2 (ja) | 2010-11-30 | 2016-06-29 | ユニベーション・テクノロジーズ・エルエルシー | 抽出された金属カルボキシレート塩を用いたオレフィンの重合方法 |
| CN103298843B (zh) | 2010-11-30 | 2015-08-19 | 尤尼威蒂恩技术有限责任公司 | 具有改进的流动特征的催化剂组合物及其制造和使用方法 |
| EP2655432B1 (en) | 2010-12-22 | 2017-08-02 | Univation Technologies, LLC | Additive for polyolefin polymerization processes |
| US9907897B2 (en) | 2011-03-23 | 2018-03-06 | Nxstage Medical, Inc. | Peritoneal dialysis systems, devices, and methods |
| US9861733B2 (en) | 2012-03-23 | 2018-01-09 | Nxstage Medical Inc. | Peritoneal dialysis systems, devices, and methods |
| US9637567B2 (en) | 2011-05-13 | 2017-05-02 | Univation Technologies, Llc | Spray-dried catalyst compositions and polymerization processes employing the same |
| US9078665B2 (en) | 2011-09-28 | 2015-07-14 | Angiodynamics, Inc. | Multiple treatment zone ablation probe |
| BR112014010900B1 (pt) | 2011-11-08 | 2020-02-18 | Univation Technologies, Llc | Método de preparar um sistema de catalisador, sistema catalisador e processo de polimerização |
| US9414881B2 (en) | 2012-02-08 | 2016-08-16 | Angiodynamics, Inc. | System and method for increasing a target zone for electrical ablation |
| RU2656343C2 (ru) | 2013-01-30 | 2018-06-05 | ЮНИВЕЙШН ТЕКНОЛОДЖИЗ, ЭлЭлСи | Способы изготовления каталитических композиций, имеющих улучшенную текучесть |
| EP3747913B1 (en) | 2014-04-02 | 2024-04-17 | Univation Technologies, LLC | Continuity compositions and olefin polymerisation method using the same |
| US10471254B2 (en) | 2014-05-12 | 2019-11-12 | Virginia Tech Intellectual Properties, Inc. | Selective modulation of intracellular effects of cells using pulsed electric fields |
| US12114911B2 (en) | 2014-08-28 | 2024-10-15 | Angiodynamics, Inc. | System and method for ablating a tissue site by electroporation with real-time pulse monitoring |
| WO2016100325A1 (en) | 2014-12-15 | 2016-06-23 | Virginia Tech Intellectual Properties, Inc. | Devices, systems, and methods for real-time monitoring of electrophysical effects during tissue treatment |
| CA2974122C (en) | 2015-01-21 | 2023-09-19 | Univation Technologies, Llc | Methods for gel reduction in polyolefins |
| EP3247548B1 (en) | 2015-01-21 | 2021-09-01 | Univation Technologies, LLC | Methods for controlling polymer chain scission |
| BR112017019133B1 (pt) | 2015-03-10 | 2021-11-23 | Univation Technologies, Llc | Método para produzir uma composição de catalisador suportado para polimerização de olefina |
| WO2016171810A1 (en) | 2015-04-20 | 2016-10-27 | Exxonmobil Chemical Patents Inc. | Supported catalyst systems and processes for use thereof |
| BR112017023052B1 (pt) | 2015-04-27 | 2022-05-10 | Univation Technologies, Llc | Composição de catalisador de polimerização de poliolefina suportada e método para a produção de composição de catalisador de polimerização de olefina suportada |
| DE102015007842A1 (de) * | 2015-06-18 | 2016-12-22 | Fresenius Medical Care Deutschland Gmbh | Dialyselösung |
| US10905492B2 (en) | 2016-11-17 | 2021-02-02 | Angiodynamics, Inc. | Techniques for irreversible electroporation using a single-pole tine-style internal device communicating with an external surface electrode |
| EP3583140B1 (en) | 2017-02-20 | 2023-03-08 | ExxonMobil Chemical Patents Inc. | Supported catalyst systems and processes for use thereof |
| EP3641850B1 (en) | 2017-06-24 | 2024-10-09 | NxStage Medical Inc. | Peritoneal dialysis fluid preparation systems |
| EP3661981A1 (en) | 2017-08-04 | 2020-06-10 | ExxonMobil Chemical Patents Inc. | Polyethylene compositions and films prepared therefrom |
| US11607537B2 (en) | 2017-12-05 | 2023-03-21 | Virginia Tech Intellectual Properties, Inc. | Method for treating neurological disorders, including tumors, with electroporation |
| US11364328B2 (en) | 2018-02-28 | 2022-06-21 | Nxstage Medical, Inc. | Fluid preparation and treatment devices methods and systems |
| US11311329B2 (en) | 2018-03-13 | 2022-04-26 | Virginia Tech Intellectual Properties, Inc. | Treatment planning for immunotherapy based treatments using non-thermal ablation techniques |
| US11925405B2 (en) | 2018-03-13 | 2024-03-12 | Virginia Tech Intellectual Properties, Inc. | Treatment planning system for immunotherapy enhancement via non-thermal ablation |
| CN112088172A (zh) | 2018-04-26 | 2020-12-15 | 埃克森美孚化学专利公司 | 在脂族和脂环族烃溶剂中制备非配位阴离子型活化剂的方法 |
| WO2019246069A1 (en) | 2018-06-19 | 2019-12-26 | Exxonmobil Chemical Patents Inc. | Polyethylene compositions and films prepared therefrom |
| US11950835B2 (en) | 2019-06-28 | 2024-04-09 | Virginia Tech Intellectual Properties, Inc. | Cycled pulsing to mitigate thermal damage for multi-electrode irreversible electroporation therapy |
| US12214189B2 (en) | 2019-07-24 | 2025-02-04 | Virginia Tech Intellectual Properties, Inc. | Fourier analysis spectroscopy for monitoring tissue impedance changes and treatment outcome during electroporation-based-therapies |
| WO2021119089A1 (en) | 2019-12-11 | 2021-06-17 | Exxonmobil Chemical Patents Inc. | Processes for introduction of liquid activators in olefin polymerization reactions |
| US20230141606A1 (en) | 2020-03-25 | 2023-05-11 | Exxonmobil Chemical Patents Inc. | Alkylation of Transition Metal Coordination Catalyst Complexes |
| WO2021262838A1 (en) | 2020-06-26 | 2021-12-30 | Exxonmobil Chemical Patents Inc. | Copolymers composed of ethylene, a-olefin, non-conjugated diene, and substituted styrene and articles therefrom |
| WO2021262842A1 (en) | 2020-06-26 | 2021-12-30 | Exxonmobil Chemical Patents Inc. | COPOLYMERS OF ETHYLENE, α-OLEFIN, NON-CONJUGATED DIENE, AND ARYL-SUBSTITUTED CYCLOALKENE, METHODS TO PRODUCE, BLENDS, AND ARTICLES THEREFROM |
| WO2022035484A1 (en) | 2020-08-10 | 2022-02-17 | Exxonmobil Chemical Patents Inc. | Methods for delivery of non-aromatic solutions to polymerization reactors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61502943A (ja) * | 1984-06-22 | 1986-12-18 | ビ−チ、リチャ−ド・エル | 電解質溶液およびその生体内における使用 |
| DE3812525C1 (ru) * | 1988-04-15 | 1989-06-22 | Fresenius Ag, 6380 Bad Homburg, De | |
| US5679650A (en) | 1993-11-24 | 1997-10-21 | Fukunaga; Atsuo F. | Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine |
| US5677290A (en) * | 1990-05-10 | 1997-10-14 | Fukunaga; Atsuo F. | Therapeutic use of adenosine compounds as surgical anesthetics |
| NZ261159A (en) | 1993-02-10 | 1997-06-24 | Astra Pharma Prod | Atp analogue and pharmaceutical compositions thereof |
| US5547942A (en) * | 1994-01-04 | 1996-08-20 | Rapaport; Eliezer | Method of treatment of diabetes mellitus by administration of adenosine 5'-t |
| JPH09143063A (ja) | 1995-11-22 | 1997-06-03 | Kose Corp | 外用に適する組成物 |
| JP3623294B2 (ja) * | 1995-11-28 | 2005-02-23 | 株式会社新素材総合研究所 | 電解質液が収容された医療用容器及びその製造方法 |
| JP3684435B2 (ja) * | 1997-08-22 | 2005-08-17 | 味の素株式会社 | ブドウ糖含有製剤 |
| CA2664159C (en) * | 1998-08-24 | 2013-06-04 | Toshio Miyata | Carbonyl-stress improving agent and peritoneal dialysate |
| US6309673B1 (en) * | 1999-09-10 | 2001-10-30 | Baxter International Inc. | Bicarbonate-based solution in two parts for peritoneal dialysis or substitution in continuous renal replacement therapy |
-
2003
- 2003-11-20 US US10/533,538 patent/US8222229B2/en not_active Expired - Fee Related
- 2003-11-20 AU AU2003284594A patent/AU2003284594B2/en not_active Ceased
- 2003-11-20 KR KR1020057008224A patent/KR101057082B1/ko not_active Expired - Fee Related
- 2003-11-20 NZ NZ539796A patent/NZ539796A/en not_active IP Right Cessation
- 2003-11-20 WO PCT/JP2003/014790 patent/WO2004045679A1/ja active Application Filing
- 2003-11-20 EP EP03774083A patent/EP1563858A4/en not_active Withdrawn
- 2003-11-20 RU RU2005119309/15A patent/RU2353400C2/ru not_active IP Right Cessation
- 2003-11-20 CA CA2506704A patent/CA2506704C/en not_active Expired - Fee Related
- 2003-11-20 JP JP2004553210A patent/JP4463687B2/ja not_active Expired - Fee Related
- 2003-11-20 CN CN2003801036528A patent/CN1713926B/zh not_active Expired - Fee Related
-
2008
- 2008-12-09 AU AU2008255178A patent/AU2008255178B2/en not_active Ceased
-
2009
- 2009-03-30 US US12/414,312 patent/US20090186850A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003284594B2 (en) | 2009-01-15 |
| EP1563858A1 (en) | 2005-08-17 |
| CN1713926B (zh) | 2010-12-22 |
| US20090186850A1 (en) | 2009-07-23 |
| RU2353400C2 (ru) | 2009-04-27 |
| JP4463687B2 (ja) | 2010-05-19 |
| AU2008255178A1 (en) | 2009-01-08 |
| CA2506704C (en) | 2013-06-25 |
| NZ539796A (en) | 2006-11-30 |
| US20060019925A1 (en) | 2006-01-26 |
| EP1563858A4 (en) | 2010-09-29 |
| WO2004045679A1 (ja) | 2004-06-03 |
| KR101057082B1 (ko) | 2011-08-16 |
| JPWO2004045679A1 (ja) | 2006-03-16 |
| KR20050075381A (ko) | 2005-07-20 |
| AU2008255178B2 (en) | 2010-07-08 |
| HK1082441A1 (en) | 2006-06-09 |
| US8222229B2 (en) | 2012-07-17 |
| AU2003284594A1 (en) | 2004-06-15 |
| CA2506704A1 (en) | 2004-06-03 |
| CN1713926A (zh) | 2005-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005119309A (ru) | Способ перитонеального диализа | |
| EP1465688B9 (en) | Bicarbonate-based solutions for dialysis therapies | |
| Fassler et al. | Magnesium toxicity as a cause of hypotension and hypoventilation: occurrence in patients with normal renal function | |
| US7053059B2 (en) | Dialysis solutions with reduced levels of glucose degradation products | |
| US6492336B1 (en) | Peritoneal dialysis fluid | |
| EP0869788B1 (en) | Compositions for the treatment of renal failure, comprising l-carnosine | |
| US20050276868A1 (en) | Bicarbonate-based peritoneal dialysis solutions | |
| Engle et al. | The use of furosemide in the treatment of edema in infants and children | |
| Page et al. | Multiple-dose pharmacokinetics of ketoconazole administered orally to gopher tortoises (Gopherus polyphemus) | |
| Anderson et al. | The treatment of pulmonary edema in the absence of renal function: a role for sorbitol and furosemide | |
| JP7034933B2 (ja) | 透析濃縮液 | |
| JPH01151462A (ja) | 腹膜灌流液 | |
| Cope | The chemical aspects of burn treatment | |
| Sam et al. | Sildenafil in dialysis patients | |
| RU2411046C2 (ru) | Способ детоксикации у больных перитонитом | |
| HK1082441B (zh) | 腹膜透析法 | |
| Fabris et al. | Rhabdomyolysis | |
| MXPA98005326A (en) | Compositions for the treatment of renal failure, comprising l-carnosine | |
| HUP0001363A2 (hu) | Szövetregeneráló oldat hashártyagyulladás regenerációjához | |
| UA75211C2 (en) | Method for treatment of liver affected by alcohol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20151121 |